Sionna Therapeutics (NASDAQ:SION) Major Shareholder Tpg Gp A, Llc Sells 250,000 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) major shareholder Tpg Gp A, Llc sold 250,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the sale, the insider directly owned 6,494,962 shares in the company, valued at approximately $259,798,480. This trade represents a 3.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sionna Therapeutics Stock Up 0.5%

Shares of SION opened at $42.60 on Tuesday. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $45.00. The business has a 50-day simple moving average of $41.26 and a two-hundred day simple moving average of $31.71. The stock has a market cap of $1.90 billion and a PE ratio of -8.75.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after buying an additional 619 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Sionna Therapeutics during the 3rd quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sionna Therapeutics during the 4th quarter worth approximately $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at $45,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SION. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Lifesci Capital initiated coverage on Sionna Therapeutics in a research report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Royal Bank Of Canada restated an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.43.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.